273 related articles for article (PubMed ID: 26934996)
1. Update on ivabradine for heart failure.
Borer JS; Tavazzi L
Trends Cardiovasc Med; 2016 Jul; 26(5):444-9. PubMed ID: 26934996
[TBL] [Abstract][Full Text] [Related]
2. Advances in the management of heart failure: the role of ivabradine.
Müller-Werdan U; Stöckl G; Werdan K
Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
[TBL] [Abstract][Full Text] [Related]
3. Ivabradine: Current and Future Treatment of Heart Failure.
Thorup L; Simonsen U; Grimm D; Hedegaard ER
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
[TBL] [Abstract][Full Text] [Related]
4. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
5. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C
Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003
[TBL] [Abstract][Full Text] [Related]
6. Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.
Pal N; Sivaswamy N; Mahmod M; Yavari A; Rudd A; Singh S; Dawson DK; Francis JM; Dwight JS; Watkins H; Neubauer S; Frenneaux M; Ashrafian H
Circulation; 2015 Nov; 132(18):1719-25. PubMed ID: 26338956
[TBL] [Abstract][Full Text] [Related]
7. Effect of Chronic Heart Rate Reduction by I(f) Current Inhibitor Ivabradine on Left Ventricular Remodeling and Systolic Performance in Middle-Aged Rats With Postmyocardial Infarction Heart Failure.
Dedkov EI; Bogatyryov Y; McCooey DS; Christensen LP; Weiss RM; Tomanek RJ
J Cardiovasc Pharmacol Ther; 2015 May; 20(3):299-312. PubMed ID: 25287895
[TBL] [Abstract][Full Text] [Related]
8. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Perry CM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
[TBL] [Abstract][Full Text] [Related]
9. Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction.
Tóth N; Soós A; Váradi A; Hegyi P; Tinusz B; Vágvölgyi A; Orosz A; Solymár M; Polyák A; Varró A; Farkas AS; Nagy N
Can J Physiol Pharmacol; 2021 Nov; 99(11):1159-1174. PubMed ID: 34636643
[TBL] [Abstract][Full Text] [Related]
10. Ivabradine: Heart Failure and Beyond.
Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
[TBL] [Abstract][Full Text] [Related]
11. Heart failure: A SHIFT from ion channels to clinical practice.
Terracciano CM; Yacoub MH
Nat Rev Cardiol; 2010 Dec; 7(12):669-70. PubMed ID: 21102629
[No Abstract] [Full Text] [Related]
12. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study.
Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P
Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004
[TBL] [Abstract][Full Text] [Related]
13. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
[TBL] [Abstract][Full Text] [Related]
14. Effect of selective heart rate reduction through sinus node I
Sisakian H; Sargsyan T; Khachatryan A
Acta Cardiol; 2016 Jun; 71(3):317-22. PubMed ID: 27594127
[No Abstract] [Full Text] [Related]
15. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
16. Ivabradine for treatment of heart failure.
Bocchi EA; Salemi VMC
Expert Opin Drug Saf; 2019 May; 18(5):393-402. PubMed ID: 31074301
[TBL] [Abstract][Full Text] [Related]
17. A Treatment Approach for Patients With Chronic Systolic Heart Failure.
Greenberg BH
Rev Cardiovasc Med; 2016; 17 Suppl 1():S22-S29. PubMed ID: 27725624
[TBL] [Abstract][Full Text] [Related]
18. Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets.
Koncz I; Szél T; Jaeger K; Baczkó I; Cerbai E; Romanelli MN; Gy Papp J; Varró A
Curr Med Chem; 2011; 18(24):3662-74. PubMed ID: 21774761
[TBL] [Abstract][Full Text] [Related]
19. [Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and health related quality of life: results from the SHIFT substudies].
Vítovec J; Spinarová L; Spinar J
Vnitr Lek; 2012; 58(7-8):612-17. PubMed ID: 23067195
[TBL] [Abstract][Full Text] [Related]
20. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
Reil JC; Reil GH; Böhm M
Trends Cardiovasc Med; 2009 Jul; 19(5):152-7. PubMed ID: 20005474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
